ROCEPHIN KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ROCEPHIN KIT (ROCEPHIN KIT).
Ceftriaxone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis and death.
| Metabolism | Ceftriaxone is not metabolized; it is excreted unchanged primarily in urine (33-67%) and bile (up to 40%). |
| Excretion | Renal (33-67% unchanged), biliary (40-50% as active drug and metabolites), fecal (minor). |
| Half-life | Terminal half-life 6-9 hours in healthy adults; prolonged to 12-15 hours in elderly and up to 30 hours in severe renal impairment (CrCl <10 mL/min). |
| Protein binding | 85-95%, primarily to albumin. |
| Volume of Distribution | 0.12-0.14 L/kg (low, indicating limited extravascular distribution, but adequate for common infections). |
| Bioavailability | IM: 100% (complete absorption). |
| Onset of Action | IV: rapid within 15-30 minutes; IM: 1-2 hours. |
| Duration of Action | Approximately 24 hours due to prolonged half-life, allowing once-daily dosing for most infections. |
| Molecular Weight | 554.58 Da (as ceftriaxone disodium salt hemiheptahydrate) |
Adult: 1-2 g IV or IM every 24 hours. Maximum 4 g/day for severe infections.
| Dosage form | INJECTABLE |
| Renal impairment | CrCl <10 mL/min: 1 g IV or IM every 24 hours. No adjustment needed for CrCl ≥10 mL/min. |
| Liver impairment | No specific Child-Pugh based adjustments required. Caution in severe hepatic impairment with concurrent renal impairment. |
| Pediatric use | Neonates (0-28 days): 50 mg/kg IV or IM once daily. Infants and children (1 month-12 years): 50-100 mg/kg IV or IM once daily, max 4 g/day. For meningitis: 100 mg/kg IV once daily, max 4 g/day. |
| Geriatric use | Same as adult dosing. Monitor renal function; adjust dose if CrCl <10 mL/min. |
| 1st trimester | Ceftriaxone crosses the placenta. Human data suggest low risk of major birth defects; however, animal studies have shown embryotoxicity at high doses. Use only if clearly needed. |
| 2nd trimester | Generally considered safe. Ceftriaxone is not associated with teratogenicity in second trimester. Monitor for maternal adverse effects. |
| 3rd trimester | Theoretically could cause kernicterus in neonates by displacing bilirubin from albumin; avoid in pregnant women near term, especially those with hyperbilirubinemia or preterm labor. |
Clinical note
Comprehensive clinical and safety monograph for ROCEPHIN KIT (ROCEPHIN KIT).
| Placental transfer | Ceftriaxone crosses the placenta readily, achieving fetal serum concentrations of 10-40% of maternal levels. Active transport not significant; diffusion-based. |
| Breastfeeding | Ceftriaxone is excreted into breast milk in low concentrations (<4% of maternal dose). It is generally considered compatible with breastfeeding due to poor oral bioavailability in infants. Monitor infant for diarrhea, rash, and candidiasis. |
■ FDA Black Box Warning
Ceftriaxone is contraindicated in neonates (≤28 days old) if they require calcium-containing IV solutions due to risk of precipitation of ceftriaxone-calcium salt in lungs and kidneys.
| Serious Effects |
Hypersensitivity to ceftriaxone or any cephalosporinHistory of severe immediate hypersensitivity reaction to penicillins or other beta-lactamsNeonates (≤28 days) receiving calcium-containing IV solutions (risk of ceftriaxone-calcium precipitation in lungs and kidneys)
| Precautions | Hypersensitivity reactions (including anaphylaxis) may occur, especially in patients with penicillin or other beta-lactam allergies., C. difficile-associated diarrhea (CDAD) may occur., Hemolytic anemia (immune-mediated) reported, monitor for signs., Concomitant use with calcium-containing IV solutions contraindicated in neonates; caution in other age groups due to precipitation risk., Biliary pseudolithiasis (reversible) may occur with high doses., May prolong prothrombin time; monitor in patients with coagulation disorders or on anticoagulants. |
| Food/Dietary | No significant food interactions. However, alcohol should be avoided during treatment and for 48 hours afterward due to possible disulfiram-like reaction (nausea, vomiting, headache). |
Loading safety data…
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | Ceftriaxone (Rocephin) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects, but there are no adequate and well-controlled studies in pregnant women. In the first trimester, the risk is considered low based on available human data. In the second and third trimesters, ceftriaxone crosses the placenta and achieves therapeutic levels in fetal serum and amniotic fluid. No specific congenital anomalies have been consistently associated. However, caution is advised in preterm infants due to risk of bilirubin displacement, but this is a neonatal concern, not fetal. Overall, the drug should be used during pregnancy only if clearly needed. |
| Fetal Monitoring | Maternal: Renal function, hepatic function, and blood counts should be monitored during prolonged therapy due to potential for neutropenia, thrombocytopenia, or elevated liver enzymes. Monitor for signs of hypersensitivity reactions. Fetal: Standard prenatal monitoring is sufficient; no specific fetal monitoring is required due to ceftriaxone use. Neonatal: In infants born to mothers treated near term, monitor for signs of jaundice or bilirubin encephalopathy, especially in preterm or hyperbilirubinemic infants, due to ceftriaxone's potential to displace bilirubin from albumin. |
| Fertility Effects | Ceftriaxone has not been associated with adverse effects on fertility in animal studies. No human data suggest impairment of male or female reproductive function. However, like other cephalosporins, it may cause transient reduction in sperm motility or count in some studies, but clinical significance is unclear. Overall, no significant impact on fertility is expected. |
| Clinical Pearls | Rocephin (ceftriaxone) is a third-generation cephalosporin with broad-spectrum activity, including against Neisseria gonorrhoeae and Streptococcus pneumoniae. Administer IV or IM; do not mix with calcium-containing solutions (risk of precipitation) in neonates. For IM injection, reconstitute with 1% lidocaine without epinephrine to reduce pain. Avoid in neonates with hyperbilirubinemia due to displacement of bilirubin from albumin. Cross-sensitivity with penicillins occurs in ~10% of patients. |
| Patient Advice | Complete the entire course of treatment even if you feel better. · Report any signs of allergic reaction (rash, itching, swelling, difficulty breathing) immediately. · This medication may cause diarrhea; if severe or persistent, contact your doctor. · For IM injections, local pain or induration may occur; apply warm compresses. · Avoid alcohol for at least 48 hours after the last dose to prevent disulfiram-like reaction. · Inform your doctor if you have a history of penicillin allergy or kidney disease. |